NewsMV
Personal imports of lower-cost prescription drugs are expected to become more difficult in the near future.
The shift signals a tightening of the regulatory perimeter around cross-border pharmaceutical purchases for individual consumers.
This development places the availability of cheaper alternatives in direct conflict with evolving import controls.
The Regulatory Shift The core development centers on the anticipated change in how personal drug imports are handled.
Keep reading